Preferred Label : Anti-RANKL Monoclonal Antibody GB-223;
NCIt definition : A monoclonal antibody directed against the receptor activator of nuclear factor kappa
beta ligand (RANKL) with potential antiosteoclast and antineoplastic activities. Upon
administration, anti-RANKL monoclonal antibody GB-223 specifically binds to RANKL
and blocks the interaction of RANKL with RANK, a receptor located on osteoclast cell
surfaces. This results in the inhibition of osteoclast activity, a decrease in bone
resorption, and a potential increase in bone mineral density. By blocking the activation
of the RANK/RANKL-mediated signaling pathway, GB-223 may also reduce tumor-associated
bone destruction and may result in tumor regression in bone tumors with high RANK
and RANKL expressions. RANKL, a protein expressed by osteoblastic cells, plays an
important role in osteoclastic differentiation and activation. Both RANKL and RANK
are overexpressed in certain bone tumors, and the RANK/RANKL-mediated signaling pathway
plays an important role in certain bone tumors.;
Molecule name : GB-223; GB 223;
NCI Metathesaurus CUI : CL1411946;
Origin ID : C174406;
UMLS CUI : C5418088;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
